Request Demo

Last update 08 May 2025

Fibrinolysis Shutdown

Last update 08 May 2025

Basic Info

Synonyms

Introduction

Acute impairment of breaking down fibrin clots leading to venous thromboembolism, stroke, and renal failure.

Drugs associated with Fibrinolysis Shutdown

BT-114143

Target

PLG

Mechanism

PLG inhibitors

Active Org.

Brilliant Pharmaceutical Co. Ltd.

Originator Org.

ScinnoHub Pharmaceutical Co., Ltd.

Active Indication

Abnormal uterine bleeding [+2]

Inactive Indication-

Drug Highest PhasePhase 1

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

HMB-TAF

Target-

Mechanism-

Active Org.-

Originator Org.

Hemab ApS

Active Indication-

Inactive Indication

Hyperfibrinolysis [+1]

Drug Highest PhaseDiscontinued

First Approval Ctry. / Loc.-

First Approval Date20 Jan 1800

Clinical Trials associated with Fibrinolysis Shutdown

NCT06493227

/ RecruitingNot ApplicableIIT

The Practice of Routine Extended Perioperative Administration of Fibrinolysis Inhibitors to Reduce the Risk of Bleeding in Cardiac Surgery. Multicenter Prospective Randomized Cluster Crossover Study

PRIORITY is a pragmatic, multi-center, cluster crossover trial that aims to evaluate whether implementing a policy of routine extended (intraoperative and 4 hour after transfer to ICU) use of fibrinolysis inhibitors leads to a decrease in post-operative blood transfusion compared to a policy that only involves intraoperative use.

Start Date01 Aug 2024

Sponsor / Collaborator

St. Petersburg State University

CTR20222910

/ RecruitingPhase 1

评价静脉注射药物BT-114143在健康受试者中的安全性、耐受性、药代动力学及生物学效应探索性研究I期临床试验

[Translation] Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and biological effects of intravenous drug BT-114143 in healthy subjects

1.单次给药与多次给药剂量递增试验主要目的：评估BT-114143在健康受试者中静脉注射单次给药、多次给药剂量递增的安全性和耐受性，确定II期推荐剂量（RP2D）。次要目的：评估BT-114143在健康受试者中静脉注射单次给药、多次给药剂量递增的药代动力学特征。探索性目的：探索BT-114143在健康受试者中的生物学效应；探索BT-114143在健康受试者中的剂量-暴露-效应关系。 2.生物学效应探索性试验主要目的：比较BT-114143与阳性对照药物单次静脉注射在健康受试者体内的抗纤溶活性和凝血指标，尽早建立药物的剂量-暴露-效应关系，为后期临床研究设计提供依据。次要目的：评估BT-114143和阳性对照药物在健康受试者中静脉注射给药的药代动力学特征。

[Translation]

1. Single and multiple dose escalation trials Primary objective: To evaluate the safety and tolerability of BT-114143 in healthy subjects by single intravenous administration and multiple dose escalation, and to determine the Phase II recommended dose (RP2D). Secondary objective: To evaluate the pharmacokinetic characteristics of BT-114143 in healthy subjects by single intravenous administration and multiple dose escalation. Exploratory objective: To explore the biological effects of BT-114143 in healthy subjects; to explore the dose-exposure-effect relationship of BT-114143 in healthy subjects. 2. Biological effect exploratory trial Primary objective: To compare the antifibrinolytic activity and coagulation indexes of BT-114143 and positive control drugs in healthy subjects after single intravenous administration, to establish the dose-exposure-effect relationship of the drug as early as possible, and to provide a basis for the design of later clinical studies. Secondary objective: To evaluate the pharmacokinetic characteristics of BT-114143 and positive control drugs in healthy subjects by intravenous administration.

Start Date06 Feb 2023

Sponsor / Collaborator

Brilliant Pharmaceutical Co. Ltd.

[+1]

NCT05540834

/ RecruitingPhase 2

A Phase 2 Safety, Dose-finding and Efficacy Study Evaluating Viscoelastic Testing (VET) Guided Tissue Plasminogen Activator (tPA) Treatment in Critically-ill Pro-thrombotic Acute Respiratory Failure

Patients with coronavirus disease (COVID) and non-COVID acute respiratory failure (ARF) may be at an increased risk of thrombosis due to increased clot formation and decreased clot lysis. This two stage study aims to utilise bedside coagulation technology to detect patients at increased risk and guide tPA treatment to maximise efficacy and safety through a personalised approach.

Start Date18 May 2022

Sponsor / Collaborator

Sydney South West Area Health Service

100 Clinical Results associated with Fibrinolysis Shutdown

100 Translational Medicine associated with Fibrinolysis Shutdown

0 Patents (Medical) associated with Fibrinolysis Shutdown

549

Literatures (Medical) associated with Fibrinolysis Shutdown

01 Feb 2025·Journal of Small Animal Practice

Hyperfibrinolysis in a dog with strongyloidiasis

Article

Author: Barker, E. N. ; Mace, C. E.

A female entire dog with a history of travel from Eastern Europe, coprophagia, and absent prophylactic treatment against parasites, developed excessive haemorrhage during elective ovariohysterectomy, resulting in abandonment of the procedure. Physical examination and abdominal ultrasound were unremarkable. Routine blood analysis was unremarkable and there was no support for angiostrongylosis or the presence of common travel‐associated infectious agents. Viscoelastic testing demonstrated hyperfibrinolysis and Baermann's faecal analysis documented Strongyloides stercoralis infection. They were treated with ivermectin, with a resolution of hyperfibrinolysis. This is the first description of transient hyperfibrinolysis associated with strongyloidiasis in the dog, although hyperfibrinolysis has been described in association with other helminth infections in the dog and in other host species. Strongyloidiasis should be considered as an uncommon cause of acquired clinical hyperfibrinolysis, particularly in dogs where common differentials have been excluded.

01 Jan 2025·Journal of the American Veterinary Medical Association

Tranexamic acid stops hyperfibrinolysis in dogs with hemorrhagic shock: a randomized, controlled clinical trial

Article

Author: Hansen, Bernie ; Hanel, Rita ; Culbreth, Laura ; Mays, Erin Long ; Rozanski, Elizabeth ; DeLaforcade, Armelle ; Majoy, Sean

AbstractOBJECTIVETo determine the effect of tranexamic acid (TXA) on clot hyperfibrinolysis (HF), defined as excessive clot lysis at 30 minutes (LY30%), with rapid thromboelastography (rTEG) or rTEG samples spiked with tissue plasminogen activator (tPA-stressed rTEG), in dogs with hemorrhagic shock.METHODSProspective blinded clinical trial at 2 teaching hospitals, March 16, 2018, to May 20, 2022. Twenty-five dogs with hemorrhagic shock and HF were treated with standard care plus either TXA (20 mg/kg; TXA group) or saline (SAL group) over 20 minutes followed by an infusion of the same dose over 8 hours. Rapid TEG and tPA-stressed rTEG assays were performed immediately before study drug administration and at 8, 12, and 24 hours afterwards (T0, T8, T12, and T24, respectively).RESULTS4 dogs died or were euthanized before the end of the study period due to disease/injury severity. All survivors had normal rTEG LY30% values after T0; the value for 1 nonsurvivor increased at T8. The tPA-stressed LY30% normalized in all TXA (n = 14) and 8 of 11 SAL dogs at T8; TXA dogs had lower median tPA-stressed rTEG LY30% values at T8 and T12 than SAL dogs (P = .001 and .02, respectively). There was no treatment effect on blood product administration or survival, and no adverse effects were attributed to TXA administration.CONCLUSIONSResuscitation with or without TXA reduced HF identified by tPA-stressed rTEG. Hyperfibrinolysis was completely suppressed at the conclusion of the 8-hour TXA infusion.CLINICAL RELEVANCEAlthough TXA treatment stopped HF, there was no effect on survival or transfusion requirements.

01 Dec 2024·Veterinary Clinical Pathology

Thromboelastography in dogs with idiopathic epilepsy treated with phenobarbital monotherapy

Article

Author: de la Fuente, C. ; Añor, S. ; García, R. ; Pastor, J.

AbstractBackgroundThromboelastography (TEG) is an effective technique to assess the efficiency of coagulation. Phenobarbital (PB) can induce hematological and coagulation disorders in both animals and humans, but its effects on hemostasis have been little investigated and are poorly understood in dogs.ObjectivesThe aim of this article was to assess coagulation using TEG in a population of dogs with idiopathic epilepsy treated with PB.Material and MethodsProspective observational study. TEG was performed in blood samples from dogs with idiopathic epilepsy that were divided in three groups: Two groups of treated dogs that were on phenobarbital treatment for less or more than 6 months, and a control group of healthy dogs. Duration of treatment, dose, phenobarbital serum concentration and selected hematological and biochemical parameters were evaluated and correlated with the TEG results.ResultsNo statistically significant differences were found between groups. None of the animals appeared to be in a hypo‐ or hypercoagulable state, however 9/19 (47,4%) dogs were classified as hyper‐fibrinolytic. A statistically significant negative relationship between MA and G values and increased fibrinolytic activity (LY30) were found. No statistically significant relationship was found between PB dose or PB blood levels and TEG parameters in either group. No bleeding complications were observed.DiscussionThe rise in fibrinolysis might be due to hepatic damage from PB, as indicated by elevated liver enzymes in many dogs with abnormal fibrinolytic patterns. Although TEG showed hyperfibrinolysis in some dogs, the presence of primary or secondary hyperfibrinolysis could not be confirmed due to the lack of D‐dimer measurements and liver biopsy. TEG’s sensitivity compared to other fibrinolysis biomarkers like PAP might also affect results.ConclusionsTThe cause of hyperfibrinolysis in epileptic dogs treated with phenobarbital remains unclear, with potential links to hepatic effects or handling, and further research is needed to assess its clinical significance.

Analysis

Perform a panoramic analysis of this field.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Fibrinolysis Shutdown

Basic Info

Related

Analysis